Welcome to Iris Biotech
For better service please confirm your country and language we detected.
For better service please confirm your country and language we detected.
Thank you very much for your interest in our products. All prices listed on our website are ex-works, Germany, and may attract customs duties when imported.
You may/will be contacted by the shipping company for additional documentation that may be required by the US Customs for clearance.
We offer you the convenience of buying through a local partner, Peptide Solutions LLC who can import the shipment as well as prepay the customs duties and brokerage on your behalf and provide the convenience of a domestic sale.
Continue to Iris Biotech GmbHSend request to US distributorNom chimique: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18-diacid-gamma-Glu-OEG-OEG)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH // Synonymes: (Aib8,Lys(C18-diacid-gamma-Glu-OEG-OEG)26,Arg34)-GLP-1 (7-37), One letter Code: H-Aib-EGTFTSDVSSYLEGQAAK(C18-diacid-gamma-Glu-OEG-OEG)EFIAWLVRGRG
from Sur demande
A GLP-1 analogue, which is acylated with a fatty acid residue, stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. The long alkyl side chain induces interaction with plasma albumin resulting in extended half-life.
This product is solely provided for research and uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Iris Biotech against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes; S. P. Marso, S. C. Bain, A. Consoli, F. G. Eliaschewitz, E. Jodar, L. A. Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M. L. Warren, V. Woo, O. Hansen, A. G. Holst, J. Pettersson, T. Vilsboll and S.-. Investigators; N Engl J Med 2016; 375: 1834-1844. https://doi.org/10.1056/NEJMoa1607141
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide; J. Lau, P. Bloch, L. Schäffer, I. Pettersson, J. Spetzler, J. Kofoed, K. Madsen, L. B. Knudsen, J. McGuire, D. B. Steensgaard, H. M. Strauss, D. X. Gram, S. M. Knudsen, F. S. Nielsen, P. Thygesen, S. Reedtz-Runge and T. Kruse; Journal of medicinal chemistry 2015; 58: 7370-7380. https://doi.org/10.1021/acs.jmedchem.5b00726
The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates; C. F. Gotfredsen, A. M. Molck, I. Thorup, N. C. Nyborg, Z. Salanti, L. B. Knudsen and M. O. Larsen; Diabetes 2014; 63: 2486-97. https://doi.org/10.2337/db13-1087